* INCLUSION CRITERIA:~* Age > 60~* Clinical Dementia Rating (global CDR) of 0.5 or 1. Memory box score must be
at least 0.5.~* Mini Mental Status Exam (MMSE) > 20~* Clinical diagnosis of (amnestic or mixed) MCI or early AD
and Memory deficit on neuropsychological or clinical testing.~* Hamilton Depression Scale score of less than or
equal to 12 on the 17-item scale~* CSF A beta 42 < 192 (+- 10%) pg/ml (given an intra-subject laboratory
variability \~ 10%)~* Medications stable for at least 4 weeks prior to screening. In particular:~ *
Participants may take stable doses of antidepressants, chronic anxiolytics or sedative hypnotics, if started at
least 4 weeks or longer prior to screening~ * Cholinesterase inhibitors and/or memantine are allowable, if
started at least 4 weeks prior to screening~ * Participants will not be asked to discontinue medications
without permission from their primary care provider (PCP) or specialist.~* Fluency in English~* At the time of
enrollment, participants must have the ability to provide informed consent and make health care decisions.~* An
informant or caregiver who has frequent contact with the participant (e.g. an average of 10 hours per week or
more) must be appointed to serve as Durable Power of Attorney (DPA) for research and medical care at NIA,
accompany the participant to clinic visits and provide historical information regarding the participant s
cognitive status, and assist participants with/administer injections of the investigational medication.~* Good
general health with no additional disease states that could interfere with the study.~
